Limits...
Liposomal Tumor Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands.

Penate Medina O, Haikola M, Tahtinen M, Simpura I, Kaukinen S, Valtanen H, Zhu Y, Kuosmanen S, Cao W, Reunanen J, Nurminen T, Saris PE, Smith-Jones P, Bradbury M, Larson S, Kairemo K - J Drug Deliv (2010)

Bottom Line: Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets.In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle.Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Sloan Kettering Institute for Cancer Research, 1275 York Ave., New York, NY 10065, USA.

ABSTRACT
Nanotechnology offers an alternative to conventional treatment options by enabling different drug delivery and controlled-release delivery strategies. Liposomes being especially biodegradable and in most cases essentially nontoxic offer a versatile platform for several different delivery approaches that can potentially enhance the delivery and targeting of therapies to tumors. Liposomes penetrate tumors spontaneously as a result of fenestrated blood vessels within tumors, leading to known enhanced permeability and subsequent drug retention effects. In addition, liposomes can be used to carry radioactive moieties, such as radiotracers, which can be bound at multiple locations within liposomes, making them attractive carriers for molecular imaging applications. Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets. In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle. Gelatinases as extracellular targets for tumor targeting offer a viable alternative for tumor targeting. Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.

No MeSH data available.


Related in: MedlinePlus

Concentrations of doxorubicin in (a) serum and (b) OV-90 xenografts in mice treated with CTT2-SL liposome and Caelyx at 0.5 and 6 hours. Data are represented as a mean of 5 mice ± SD.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3066593&req=5

fig10: Concentrations of doxorubicin in (a) serum and (b) OV-90 xenografts in mice treated with CTT2-SL liposome and Caelyx at 0.5 and 6 hours. Data are represented as a mean of 5 mice ± SD.

Mentions: Given the overall improved survival found following treatment of A2780 xenografts with CTT2-SL liposomes, studies were extended to assess treatment response in OV-90 xenograft models. As seen in Figure 10, despite the lower doses of CTT2-SL liposomes administered, efficient targeting, along with rising concentrations of doxorubicin was measured using this serous ovarian model (Figure 10(b)) over a 6-hr time interval relative to the untargeted formulation.


Liposomal Tumor Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands.

Penate Medina O, Haikola M, Tahtinen M, Simpura I, Kaukinen S, Valtanen H, Zhu Y, Kuosmanen S, Cao W, Reunanen J, Nurminen T, Saris PE, Smith-Jones P, Bradbury M, Larson S, Kairemo K - J Drug Deliv (2010)

Concentrations of doxorubicin in (a) serum and (b) OV-90 xenografts in mice treated with CTT2-SL liposome and Caelyx at 0.5 and 6 hours. Data are represented as a mean of 5 mice ± SD.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3066593&req=5

fig10: Concentrations of doxorubicin in (a) serum and (b) OV-90 xenografts in mice treated with CTT2-SL liposome and Caelyx at 0.5 and 6 hours. Data are represented as a mean of 5 mice ± SD.
Mentions: Given the overall improved survival found following treatment of A2780 xenografts with CTT2-SL liposomes, studies were extended to assess treatment response in OV-90 xenograft models. As seen in Figure 10, despite the lower doses of CTT2-SL liposomes administered, efficient targeting, along with rising concentrations of doxorubicin was measured using this serous ovarian model (Figure 10(b)) over a 6-hr time interval relative to the untargeted formulation.

Bottom Line: Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets.In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle.Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Sloan Kettering Institute for Cancer Research, 1275 York Ave., New York, NY 10065, USA.

ABSTRACT
Nanotechnology offers an alternative to conventional treatment options by enabling different drug delivery and controlled-release delivery strategies. Liposomes being especially biodegradable and in most cases essentially nontoxic offer a versatile platform for several different delivery approaches that can potentially enhance the delivery and targeting of therapies to tumors. Liposomes penetrate tumors spontaneously as a result of fenestrated blood vessels within tumors, leading to known enhanced permeability and subsequent drug retention effects. In addition, liposomes can be used to carry radioactive moieties, such as radiotracers, which can be bound at multiple locations within liposomes, making them attractive carriers for molecular imaging applications. Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets. In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle. Gelatinases as extracellular targets for tumor targeting offer a viable alternative for tumor targeting. Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.

No MeSH data available.


Related in: MedlinePlus